FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912307894> ?p ?o ?g. }

• W2912307894 endingPage "3635" @default.
• W2912307894 startingPage "3635" @default.
• W2912307894 abstract "Abstract Beta-thalassemia is a hereditary blood disorder characterized by reduced or absent synthesis of the beta-globin chain, one of the major components of adult hemoglobin (Hb). The unbalanced synthesis of globin chains leads to a relative excess of alpha-globin and heme, resulting in hemichrome-induced cellular damage in bone marrow erythroblasts and circulating erythrocytes. This, in turn, contributes to ineffective erythropoiesis, hemolysis and reduced red blood cell (RBC) survival, hallmarks of beta-thalassemia. We have previously reported that reduction in cellular heme synthesis by bitopertin, an oral, reversible, potent and selective glycine transporter 1 (GlyT1) inhibitor, positively impacts the disease pathology in a beta-thalassemia mouse model. It was hypothesized that reduced heme synthesis down-regulates globin production and as such diminishes the alpha-chain excess, driving the observed improvements in Hb, hemolysis and RBC survival in beta-thalassemia mice. In study BP39642 (NCT03271541), a multicenter, single arm, proof-of-mechanism study, we investigated the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple oral doses of bitopertin in adult patients with non-transfusion-dependent (NTD) beta-thalassemia. Participants underwent a 6-week dose-escalation period followed by up to 10 weeks of treatment at the attained target dose. Tolerability was acceptable in NTD beta-thalassemia patients. Adverse events observed were in line with expectations from previous trials, with transient but repetitive headache and dizziness being the most prominent events. The PK characteristics of bitopertin were consistent with healthy volunteers and non-thalassemic patients. PD data from 8 patients treated for 8 week showed that Hb levels, the primary efficacy outcome measure in this study, decreased from a mean value of 8.5 g/dL at baseline to 8.1 g/dL at week 9 (-5.2%). The mean corpuscular hemoglobin (MCH) content of erythrocytes and reticulocytes decreased by 2 pg (-9.3%) and 1.8 pg (-7.8%), respectively. Absolute counts of reticulocytes remained largely unchanged over the treatment period (+1.4%), while the total number of circulating RBCs increased from 4.3 x10E12/L to 4.5 x10E12/L (+6%). Based on these results, we concluded that treatment with bitopertin in NTD beta-thalassemia patients results in an expected inhibition of heme biosynthesis. Contrary to the observations in beta-thalassemia mice this did not lead to an improved disease phenotype in patients. We postulate that the negative effects of bitopertin on Hb synthesis were not sufficiently compensated by the observed increase in RBC count. We will present and discuss data that led to an early termination of the study and the implications for future research in this field. Disclosures Taher: Ionis Pharmaceuticals: Consultancy; Celgene Corp.: Research Funding; La Jolla Pharmaceutical: Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Protagonist Therapeutics: Consultancy. Viprakasit:F. Hoffmann-La Roche Ltd: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Protagonist Therapeutics: Consultancy, Research Funding; Agios: Consultancy, Research Funding. Cappellini:Sanofi/Genzyme: Membership on an entity's Board of Directors or advisory committees; Vifor: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria. Kraus:F. Hoffmann-La Roche Ltd: Employment. Cech:F.Hoffmann-La Roche Ltd: Employment. Dietmar:F. Hoffmann-La Roche Ltd: Employment. Winter:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Mazer:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Nave:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Dukart:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Schaedeli Stark:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Koerner:F. Hoffmann-La Roche Ltd: Employment. Khwaja:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Hermosilla:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership." @default.
• W2912307894 created "2019-02-21" @default.
• W2912307894 creator A5001257793 @default.
• W2912307894 creator A5029104997 @default.
• W2912307894 creator A5030884170 @default.
• W2912307894 creator A5052192377 @default.
• W2912307894 creator A5052763004 @default.
• W2912307894 creator A5058078318 @default.
• W2912307894 creator A5065194793 @default.
• W2912307894 creator A5066002078 @default.
• W2912307894 creator A5070232710 @default.
• W2912307894 creator A5072070335 @default.
• W2912307894 creator A5072237761 @default.
• W2912307894 creator A5080150203 @default.
• W2912307894 creator A5081147231 @default.
• W2912307894 creator A5089053900 @default.
• W2912307894 date "2018-11-29" @default.
• W2912307894 modified "2023-10-17" @default.
• W2912307894 title "Phase 2 Clinical Trial Results for Bitopertin, an Oral Glycine Transporter 1 Inhibitor, in Patients with Non-Transfusion Dependent Beta-Thalassemia" @default.
• W2912307894 doi "https://doi.org/10.1182/blood-2018-99-114776" @default.
• W2912307894 hasPublicationYear "2018" @default.
• W2912307894 type Work @default.
• W2912307894 sameAs 2912307894 @default.
• W2912307894 citedByCount "2" @default.
• W2912307894 countsByYear W29123078942020 @default.
• W2912307894 countsByYear W29123078942023 @default.
• W2912307894 crossrefType "journal-article" @default.
• W2912307894 hasAuthorship W2912307894A5001257793 @default.
• W2912307894 hasAuthorship W2912307894A5029104997 @default.
• W2912307894 hasAuthorship W2912307894A5030884170 @default.
• W2912307894 hasAuthorship W2912307894A5052192377 @default.
• W2912307894 hasAuthorship W2912307894A5052763004 @default.
• W2912307894 hasAuthorship W2912307894A5058078318 @default.
• W2912307894 hasAuthorship W2912307894A5065194793 @default.
• W2912307894 hasAuthorship W2912307894A5066002078 @default.
• W2912307894 hasAuthorship W2912307894A5070232710 @default.
• W2912307894 hasAuthorship W2912307894A5072070335 @default.
• W2912307894 hasAuthorship W2912307894A5072237761 @default.
• W2912307894 hasAuthorship W2912307894A5080150203 @default.
• W2912307894 hasAuthorship W2912307894A5081147231 @default.
• W2912307894 hasAuthorship W2912307894A5089053900 @default.
• W2912307894 hasConcept C111113717 @default.
• W2912307894 hasConcept C112705442 @default.
• W2912307894 hasConcept C126322002 @default.
• W2912307894 hasConcept C197934379 @default.
• W2912307894 hasConcept C203014093 @default.
• W2912307894 hasConcept C2777799968 @default.
• W2912307894 hasConcept C2777940137 @default.
• W2912307894 hasConcept C2778248108 @default.
• W2912307894 hasConcept C2778375690 @default.
• W2912307894 hasConcept C2778917026 @default.
• W2912307894 hasConcept C2779703530 @default.
• W2912307894 hasConcept C2779902561 @default.
• W2912307894 hasConcept C2780844101 @default.
• W2912307894 hasConcept C71924100 @default.
• W2912307894 hasConcept C90924648 @default.
• W2912307894 hasConcept C98274493 @default.
• W2912307894 hasConceptScore W2912307894C111113717 @default.
• W2912307894 hasConceptScore W2912307894C112705442 @default.
• W2912307894 hasConceptScore W2912307894C126322002 @default.
• W2912307894 hasConceptScore W2912307894C197934379 @default.
• W2912307894 hasConceptScore W2912307894C203014093 @default.
• W2912307894 hasConceptScore W2912307894C2777799968 @default.
• W2912307894 hasConceptScore W2912307894C2777940137 @default.
• W2912307894 hasConceptScore W2912307894C2778248108 @default.
• W2912307894 hasConceptScore W2912307894C2778375690 @default.
• W2912307894 hasConceptScore W2912307894C2778917026 @default.
• W2912307894 hasConceptScore W2912307894C2779703530 @default.
• W2912307894 hasConceptScore W2912307894C2779902561 @default.
• W2912307894 hasConceptScore W2912307894C2780844101 @default.
• W2912307894 hasConceptScore W2912307894C71924100 @default.
• W2912307894 hasConceptScore W2912307894C90924648 @default.
• W2912307894 hasConceptScore W2912307894C98274493 @default.
• W2912307894 hasIssue "Supplement 1" @default.
• W2912307894 hasLocation W29123078941 @default.
• W2912307894 hasOpenAccess W2912307894 @default.
• W2912307894 hasPrimaryLocation W29123078941 @default.
• W2912307894 hasRelatedWork W124095773 @default.
• W2912307894 hasRelatedWork W1981919419 @default.
• W2912307894 hasRelatedWork W2108667952 @default.
• W2912307894 hasRelatedWork W2118103190 @default.
• W2912307894 hasRelatedWork W2151573971 @default.
• W2912307894 hasRelatedWork W2163438420 @default.
• W2912307894 hasRelatedWork W2789595183 @default.
• W2912307894 hasRelatedWork W2891562328 @default.
• W2912307894 hasRelatedWork W2977564049 @default.
• W2912307894 hasRelatedWork W4224509147 @default.
• W2912307894 hasVolume "132" @default.
• W2912307894 isParatext "false" @default.
• W2912307894 isRetracted "false" @default.
• W2912307894 magId "2912307894" @default.
• W2912307894 workType "article" @default.